TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT05798897: Safety and Preliminary Efficacy of MT-601 in Patients With Relapsed/Refractory Lymphoma

Sponsor: Marker Therapeutics, Inc. · Phase: PHASE1 · Area: ONCOLOGY · Target Enrollment: 79 pts

Competing Trials Overlap

6 Active Trials

Excess Burn Exposure

$1,225,224

Rescue Site Savings

+$816,816

Unlock Full NCT05798897 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT05798897 Rescue Dossier →